Accolade, Inc. (NASDAQ:ACCD – Get Free Report) was the target of a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 3,600,000 shares, a decline of 6.5% from the May 31st total of 3,850,000 shares. Based on an average daily volume of 688,100 shares, the days-to-cover ratio is presently 5.2 days.
Insider Buying and Selling at Accolade
In other news, CAO Colin Mchugh sold 5,543 shares of the company’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $6.62, for a total value of $36,694.66. Following the sale, the chief accounting officer now directly owns 50,177 shares of the company’s stock, valued at approximately $332,171.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last ninety days, insiders have sold 14,303 shares of company stock valued at $100,342. 8.20% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Accolade
Several institutional investors have recently made changes to their positions in the business. Swiss National Bank lifted its stake in shares of Accolade by 1.7% in the 1st quarter. Swiss National Bank now owns 137,500 shares of the company’s stock worth $1,441,000 after purchasing an additional 2,300 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Accolade by 15.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,540 shares of the company’s stock worth $205,000 after acquiring an additional 2,586 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Accolade by 39.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,584 shares of the company’s stock worth $199,000 after acquiring an additional 4,656 shares in the last quarter. AJOVista LLC purchased a new stake in Accolade in the 4th quarter worth approximately $68,000. Finally, Allspring Global Investments Holdings LLC purchased a new stake in Accolade in the 1st quarter worth approximately $87,000. Institutional investors own 84.99% of the company’s stock.
Analyst Ratings Changes
Check Out Our Latest Stock Report on ACCD
Accolade Price Performance
Shares of NASDAQ:ACCD opened at $3.54 on Tuesday. The firm’s 50 day moving average price is $7.09 and its 200-day moving average price is $9.66. Accolade has a twelve month low of $3.48 and a twelve month high of $15.36. The company has a quick ratio of 2.80, a current ratio of 2.80 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $283.24 million, a PE ratio of -3.05 and a beta of 2.00.
Accolade (NASDAQ:ACCD – Get Free Report) last issued its quarterly earnings data on Thursday, June 27th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.13. Accolade had a negative net margin of 20.62% and a negative return on equity of 20.30%. The firm had revenue of $110.50 million for the quarter, compared to analysts’ expectations of $105.22 million. During the same quarter in the prior year, the business earned ($0.52) EPS. The business’s quarterly revenue was up 18.6% on a year-over-year basis. Equities research analysts expect that Accolade will post -1.23 EPS for the current year.
About Accolade
Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.
Featured Stories
- Five stocks we like better than Accolade
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- What Are Dividend Champions? How to Invest in the Champions
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Accolade Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accolade and related companies with MarketBeat.com's FREE daily email newsletter.